Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting
“Sermonix is delighted to have quickly completed enrollment of this I-SPY 2 EOP study of lasofoxifene as a neoadjuvant endocrine therapy, complementing our ongoing ELAINE-3 Phase 3 combination study of lasofoxifene with abemaciclib in the ESR1-mutated metastatic breast cancer setting,” said Dr. David Portman, Sermonix founder and chief executive officer. “With a recent preclinical study also suggesting lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumors, and other data suggesting beneficial effects of lasofoxifene on genitourinary syndrome of menopause and bone health, we are focused on exploring the drug’s broad potential as a therapy for people confronted with breast cancer – and one that does so while potentially offering unique quality of life benefits across the treatment continuum.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us